Market Overview

Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades

Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades
Related CNCE
34 Biggest Movers From Yesterday
41 Biggest Movers From Yesterday

Concert Pharmaceuticals Inc (NASDAQ: CNCE) announced Friday the Patent Trial and Appeal Board decided not to grant the company a Post Grant Review petition in the patent '335 dispute with Incyte Corporation (NASDAQ: INCY).

The Analyst

Mizuho Securities' Difei Yang decided to downgrade the stock from Buy to Neutral and maintained the price target at $23.

The Thesis

The stock traded sharply lower on the news about the patent '335 dispute, but the decision isn't going to have implications for the ultimate outcome of the trial, said Yang, though she expects the litigation overhang will remain in the foreseeable future. The analyst sees the stock as fairly valued and decided to leave unchanged her peak revenue estimates of $130 million in 2028 for CTP-543 and $110 million in 2028 for AVP-786.

Two of Concert's Phase 3 trials are now expected in 2019 instead of 2018, and a new neurology candidate could be disclosed by 2Q 2018, said Yang. The new drug could lead to a higher stock price.

Price Action

The stock plunged more than 27 percent after the release of the news and recently traded around $20.

Related Links:

Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making

Key Takeaways From The JPMorgan Healthcare Conference

Latest Ratings for CNCE

May 2018H.C. WainwrightMaintainsBuyBuy
Mar 2018H.C. WainwrightMaintainsBuyBuy
Jan 2018MizuhoDowngradesBuyNeutral

View More Analyst Ratings for CNCE
View the Latest Analyst Ratings

Posted-In: Difei Yang Mizuho SecuritiesAnalyst Color Biotech Downgrades Health Care Analyst Ratings General Best of Benzinga


Related Articles (INCY + CNCE)

View Comments and Join the Discussion!

Signet Jewelers' Blemishes Lead To RBC Downgrade

Bank Of America On AMD, Nvidia, And Intel's 'Processor-Gate'